Halozyme Therapeutics, Inc. (RV7.F)

35,95 -0,23 (-0,64%) Börsenschluss: 08:01AM CEST

Halozyme Therapeutics, Inc.

12390 El Camino Real
San Diego, CA 92130
United States
858 794 8889
https://halozyme.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 373

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.	President, CEO & Director	1,7M	5,32M	1963
Ms. Nicole LaBrosse	Senior VP & CFO	793,87k	N/A	1983
Dr. Michael J. LaBarre Ph.D.	Senior VP & Chief Technical Officer	788,76k	2,43M	1964
Mr. Mark Snyder Esq.	Senior VP & Chief Legal Officer	853,23k	N/A	N/A
Ms. Cortney Caudill M.B.A.	Chief Operations Officer	N/A	N/A	N/A
Ms. Tram Bui	Head of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Amy Marinne Fox	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Kristin Schwartzbauer	Head of Quality	N/A	N/A	N/A
Mr. Gary Grote	Chief Commercial Officer	N/A	N/A	N/A
Dr. Christopher Wahl M.B.A., M.D.	Chief Business Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 1. Die grundlegenden Scores sind Audit: 4, Vorstand: 1, Shareholderrechte: 3, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.